FTC approves final settlement on generic drug divestiture
The Federal Trade Commission gave final approval to a settlement that satisfies its concerns that Impax Laboratories Inc.’s purchase of CorePharma would be anticompetitive....To view the full article, register now.
Already a subscriber? Click here to view full article